- Island Pharmaceuticals (ILA) signs a contract for a clinical trial site for its Phase 2 study on dengue fever
- The trial is designed to test ISLA-101, a drug candidate repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases
- Island anticipates the Phase 2a clinical trial will begin dosing subjects in early 2022 and will take up to 12 months to complete
- Island Pharmaceuticals dips 1.61 per cent, trading at 30.5 cents at 2:55 pm AEDT
Island Pharmaceuticals (ILA) has signed a contract for a clinical trial site for its Phase 2 study.
The study is designed to test ISLA-101, a drug candidate being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases.
The PEACH trial is a Phase 2a, randomised, placebo-controlled study for the prophylactic examination of an antiviral in a dengue model, involving up to 16 participants.
To support the trial, Island has teamed up with the Research Foundation for The State University of New York (SUNY) on behalf of Upstate Medical University, Syracuse NY, where the trial will be conducted.
Dr Kristopher Paolino has been appointed the principal investigator of the trial.
“With leadership in place, plus this key contract with SUNY, we are well on our way to initiating the PEACH study in early 2022,” said Island’s CEO, Dr David Foster.
Island is sponsor of the study and will pay around US$677,000 (A$915,400) to SUNY in set tranches, plus provide the ISLA-101 GMP drug product for the prophylactic arm of the clinical trial.
Under the agreed terms of the PEACH trial, any new inventions discovered during the trial will be owned by Island Pharmaceuticals and, at the conclusion, Island and SUNY will cooperate on the publication of the study’s results.
It is anticipated that the Phase 2a clinical trial will begin dosing subjects in early 2022 and will take up to 12 months to complete.
Island Pharmaceuticals dipped 1.61 per cent, trading at 30.5 cents per share at 2:55 pm AEDT.